IP Library Granted Patent US 9,012,480
Granted Patent B2
US 9,012,480 · App. 13/707,863 · Granted Apr 21, 2015

Topical therapy for migraine

Inventor: Ronald Aung-Din (Sarasota, FL)
Assignee: AFGIN Pharma LLC
A61K31/4045A61K31/405
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,480
App. No.
13/707,863
Granted
Apr 21, 2015
Kind
B2
Abstract

The invention is directed to formulations and methods of treating a migraine and/or cluster headache with a serotonin agonist, pharmaceutically acceptable salt thereof, or derivative thereof.

Claims (22)

1. A method for treating a migraine or cluster headache comprising: applying a therapeutically effective amount of a topically effective triptan topically to the skin at the posterior cervical area of a human patient in close proximity to the brain stem, the topical formulation comprising triptan in an immediate release topical vehicle and providing rapid delivery of the triptan for immediate absorption at the posterior cervical area of the human patient, to provide relief of a migraine or cluster headache which is occurring or is imminent in the patient.

2. The method of claim 1 , further comprising preparing the topical formulation as a preparation selected from the group consisting of cream, gel, ointment, paste, lotion, emulsion, viscous liquid, foam, and a semisolid.

3. The method of claim 2 , further comprising preparing the topical formulation in an aqueous based vehicle.

4. The method of claim 3 , wherein the topical formulation is selected from the group consisting of an cream, ointment, gel and lotion.

5. The method of claim 1 , wherein the patient experiences relief of the migraine or cluster headache within about 2 hours after applying the topical formulation.

6. The method of claim 1 , wherein the triptan is selected from the group consisting of sumatriptan, naratriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, and pharmaceutically acceptable salts thereof.

7. The method of claim 6 , wherein the triptan is selected from the group consisting of sumatriptan, sumatriptan succinate, and mixtures thereof.

8. The method of claim 7 , wherein said amount of the triptan is in an amount of from about 0.5 mg to about 200 mg.

9. The method of claim 1 , wherein said amount of the triptan is from about 0.5 to about 200 mg; and said unit dose providing relief from a migraine or cluster headache within about 2 hours after topical administration to said human patient.

10. The method of claim 1 , further comprising applying a second application of said triptan to the same or different headache region within about 2 hours after applying the first application.

11. The method of claim 1 , further comprising applying the formulation to an area of intact skin in the range of about 20 cm 2 to about 60 cm 2 .

12. The method of claim 1 , further comprising reducing the side effects of the triptan as compared to oral administration of the triptan by applying the formulation to the posterior cervical area.

13. A method for treating a migraine or cluster headache comprising:

applying a dose of a topical formulation containing a therapeutically effective amount of a triptan selected from the group consisting of sumatriptan, naratriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, and pharmaceutically acceptable salts thereof topically to the skin at the posterior cervical area of a human patient in close proximity to the brain stem, the topical formulation comprising the triptan providing rapid delivery of the triptan for immediate absorption at the posterior cervical area of the human patient, to provide relief of a migraine or cluster headache which is occurring or is imminent in said patient, wherein the dose provides relief from a migraine or cluster headache within about 2 hours after topical administration to the human patient.

14. The method of claim 13 , wherein the topical formulation is selected from the group consisting of a cream, ointment, gel, lotion, paste, emulsion, viscous liquid, foam, and a semisolid.

15. The method of claim 14 , wherein the triptan is selected from the group consisting of rizatriptan, zolmitriptan, frovatriptan, and pharmaceutically acceptable salts thereof.

16. The method of claim 13 , further comprising reducing the side effects of the triptan as compared to oral administration of the triptan by applying the formulation to the posterior cervical area.

17. The method of claim 13 , further comprising providing the dose of the triptan in a metered dose device containing multiple unit doses of the triptan.

18. The method of claim 13 , wherein the triptan is rizatriptan or a pharmaceutically acceptable salt thereof.

19. The method of claim 13 , wherein the patient experiences pain relief within less than about 30 minutes after application of the dose.

20. The method of claim 13 , wherein the triptan is zolmitriptan or a pharmaceutically acceptable salt thereof.

21. The method of claim 13 , wherein said amount of the triptan is in an amount of from about 0.5 mg to about 200 mg.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2026
From: PSYCHECEUTICAL, INC.
To: GOLABS RESEARCH AND DEVELOPMENT, LLC.
Reel/Frame 075405/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2024
From: DEF LLC
To: PSYCHECEUTICAL INC.
Reel/Frame 067243/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2024
From: AFGIN PHARMA LLC
To: PSYCHECEUTICAL INC.
Reel/Frame 066236/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2020
From: AFGIN PHARMA, LLC
To: DEF LLC
Reel/Frame 054620/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2013
From: AUNG-DIN, RONALD
To: AFGIN PHARMA LLC
Reel/Frame 031552/0353 →
Continuity (5)
Continuation 12460966 · Jul 27, 2009
Division 11999093 · Dec 3, 2007
Continuation 10163234 · Jun 5, 2002
Provisional Application 60296286 · Jun 5, 2001
Related Publication 20130150423A1 · Jun 13, 2013